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ABSTRACT
Theprokaryoticbrecombinasecatalyzessite-specific
recombination between two directly oriented min-
imal six sites in chromatin-integrated substrates.
Here, we demonstrate that an enhanced green fluo-
rescent protein (EGFP)-fused version of b recombi-
nase (b-EGFP) is fully active, retaining most specific
activity. It is used to develop a recombination-
dependent activatable gene expression (RAGE)
system based on the androgen receptor (AR) ligand-
bindingdomain(LBD).Twohybridmolecules,adirect
fusion of the LBD-AR to the C-terminus of b recom-
binase (b-AR) and a triple fusion of b-EGFP to the
same ligand-binding domain (b-EGFP-AR), were
engineered and their subcellular behavior, stability
and catalytic activity were evaluated. Both chimeric
b recombinase proteins showed in vivo inducible
recombinogenic activity dependent on addition of
an androgen receptor agonist, although the b-AR
fusion protein demonstrated more accurate ligand-
dependent translocation from cytoplasm to nucleus.
INTRODUCTION
Site-speciﬁc recombinases have become a standard tool for
conditional gene modiﬁcations, as an alternative to classical
gene targeting technologies (1–3). These systems allow pro-
grammed inter- and intramolecular recombination that over-
come some limitations of classical knockout systems, such as
embryonic lethality or generation of compensation mecha-
nisms. Cre-loxP and Flp-FRT are currently the systems of
choice, due to their ability to induce targeted changes in
animal models and in plants (4). Using these systems,
tissue-speciﬁc,conditional and inducible gene targeting events
have been reported in a wide variety of tissues and organs
(5–8); in addition, the Int-attP site-speciﬁc recombination
(SSR) system from lambda phage recently proved to be suc-
cessfulinplants(9).Thereare fewreportsonthecombineduse
of these systems (10); it is thus necessary to characterize other
SSR systems that could be used as an alternative to or in
combination with existing models.
b Recombinase from the Gram-positive plasmid pSM19035
induces speciﬁc intramolecular recombination in mammalian
cells, in both episomal plasmids and chromatin-associated
substrate structures (11,12). Plasmid pSM19035 has an
unusual structure, as almost 80% of the molecule consists
of a repeated sequence and two replication origins (13).
Since replication of this plasmid follows the classical theta
model, a mechanism must exist to ensure its complete replica-
tion (inversion) and maximization of plasmid segregation
(resolution). Development of an in vitro recombination system
based on puriﬁed b recombinase showed both inversion and
deletion activities associated to the protein, delimited the
sequences required for directing the SSR reactions and char-
acterized the requirements for both reactions (13,14). Unlike
Cre and Flp, which belong to the Int recombinase family,
b recombinase is included in the resolvase/invertase family
and catalyzes exclusively intramolecular recombination
events (14–16). At difference from Cre and Flp SSR, which
do not require additional factors [reviewed in 17,18), for dele-
tion, b recombinase requires a supercoiled substrate and a
chromatin-associated protein (e.g. bacterial Hbsu or eukary-
otic HMG1 proteins) (16). The mammalian cell environment
can provide such a host factor (12), and nuclear genomic DNA
supercoiling seems to be sufﬁcient for b recombinase function
(11). The b recombinase-dependent SSR that uses the minimal
deﬁned recognition sequences (six) was denominated b-six
(12). Owing to its speciﬁc characteristics, particularly to its
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SSR system was proposed as the ideal choice when several
independently controlled recombination events are needed in
the same animal or cell (12). This would prevent intermolecu-
lar recombination events between remaining recombination
sites, which can occur when integrase family recombinases
are used. Combined use of the b-six system with the Cre- and/
or Flp-based SSR systems would expand current possibilities
for programmed modiﬁcation of eukaryotic genomes in
complex spatio-temporal combinations.
Controlled induction of recombinogenic activity of SSR
systems is a highly desirable feature. A ﬁrst level of control
is obtained by lineage or cell type selective expression of the
recombinase activity. The second is achieved using an
inducible promoter or by including a protein module in the
recombinase activity that is able to maintain the recombinase
in the cytoplasmic compartment; following interaction with
inductor molecules, it promotes importation of the recombi-
nase activity to the nuclear compartment [reviewed in (19)].
This latter method has been developed successfully in the Cre-
loxP and Flp-FRT systems, using the ligand-binding domain
(LBD) of the estrogen (ER), androgen (AR) or the proges-
terone (PR) nuclear receptors. The combined use of tissue- or
cell type-speciﬁc promoters with fusion proteins of recombi-
nase with nuclear receptor LBD allows spatio-temporal
control of the targeted genomic modiﬁcation (20).
Here, we explored the development of such an inducible
SSR system using the b-six model and the androgen receptor
LBD (AR-LBD). The AR is located primarily in cytoplasm;
after binding to an AR agonist it translocates to the nucleus;
after dimerization, it binds speciﬁc DNA regions and activates
transcription of its target genes (21). The AR is composed of
917 amino acids, with the C-terminal portion forming the
LBD, although functional regulatory interactions are
described between the N- and C-termini (21). Modulation
of FLP (22) and Cre (23) recombinogenic activity by fusion
of the LBD-AR has been demonstrated. Our results indicate
that b recombinase fused in its C-terminus to LBD-AR or a
triple fusion of b recombinase in the same way could be
controlled by addition of selective AR agonists.
MATERIALS AND METHODS
Plasmids
Plasmids pBT233, pRecombiner and pb-EGFP have been
described previously (12,24). Plasmid pEGFP-N1 (Clontech,
Palo Alto, CA) and pTA-cloning vector (Promega, Madison,
WI) were from commercial sources.
Generation of pLuc and psps-Luc
For recombination-activated gene expression, we designed
and obtained a set of two vectors. The luciferase gene
was obtained from the pRVSINloxPTP-Luc-IRES-DNGFR
HindIII/XbaI and ligated in the same restriction sites to
pCDNA3.1 Hygro. The resulting plasmid, p-Luc-Hygro,
was digested with MluI/NheI to eliminate the CMV promoter,
which was replaced with the EF-1a promoter from the pEF-
4
aMyc-His after MluI and SpeI digestion. We thus obtained
the pLuc positive control for luciferase expression in our
experiments. The recombination substrate was obtained by
cloning the six-pur-six (sps) cassette from pRecombiner
(12) in pLuc using HindIII. Resulting plasmids were puriﬁed
for transfection using Qiagen columns (Qiagen, Hilden,
Germany), following the manufacturer’s protocols.
Retroviral vector construction
pLZR-ires-EGFP and pLZRb-EGFP vector development has
been described previously (12). To generate pLZR-b-IRES-
EGFP, we introduced the b recombinase gene in the pLZR-
ires-EGFP vector, and appropriate 50 BamHI and 30 EcoRI
sites on the b gene from pBT233. Using primers beta
(RES)-5 (50-GAGAGAGGATCCATGGCTAAAATTGGT
TATG-30) and beta(RES)-3 (50-GTGTGTGAATTCTTAAC-
TATCCCTCTTTCC-30), we performed PCR ampliﬁcation
with Taq Gold polymerase (Roche) using the supplier’s stan-
dard conditions (one denaturation cycle at 94 C for 2 min,
followed by 35 cycles at 94 C for 15 s; 59 C for 30 s; 72 C for
1 min and a ﬁnal elongation cycle at 72 C for 5 min). The
ampliﬁcation product was ligated to BamHI/EcoRI-digested
pLZR-ires-EGFP following the standard cloning procedures,
resulting in pLZR-b-ires-EGFP.
To generate pLZR-b-AR(LBD)-ires-EGFP, the LBD-AR
was obtained by PCR ampliﬁcation of the pAdapt.
hrtTA-VP16-AR-ires-Egfp plasmid (received from
Dr K. Anastassiadis) with the primers SAR (50-CAGCCGCG-
GATGCATGTGTCACACATTG AAGG-30) and ARNN (50-
CAGGCGGCCGCAGGCGCCTCACTGGGTGTGGAAAT-
AG ATGG-30). The ampliﬁed product was puriﬁed and cloned
using the pTA-Cloning vector system, to give the pTA-S/NN
plasmid. This was digested with SacII and NotI and the res-
ulting LBD-containing fragment cloned in the same pb-EGFP
restriction sites, resulting in the pb-LBD vector containing
the fusion open reading frame (ORF) in a correct translation
phase. The BglII, PvuII and NarI fragment containing the
b-LBD ORF from this vector was cloned in pLZR-ires-
EGFP vector, digested with BamHI/SfuI, resulting in the
pLZR-b-LBD-ires-EGFP retroviral vector.
For the pLZR-b-EGFP-AR(LBD), the LBD-AR was
obtained by PCR ampliﬁcation of the same parental plasmid
with the primers BAR (50-CAGAGATCTATGCATGTGT-
CACACA TTGAAGG-30) and ARNH (50-CAGAAGCTTGC-
GGCCGCTCACTGGGTGTGGAAATAG ATGG-30). The
ampliﬁcation product was puriﬁed and cloned using the
pTA-Cloning vector system, to give the pTA-B/NH plasmid.
This was digested with BglII and HindIII, and the resulting
LBD-containing fragment was cloned in the same restriction
sites of pEGFP-N1 (Clontech), to give the pEGFP-LBD vector
containing the fusion ORF in a correct translation phase. After
AgeI/NotI digestion, we obtained the LBD linked to a 30-
EGFP fragment that was ligated to the 50-EGFP fragment
of pb-EGFP, which had been digested as above. The resulting
plasmid, pb-EGFP-LBD, was XhoI/NotI-digested and ligated
to pLZR-IRES-EGFP, giving rise to the pLZR-b-EGFP-LBD
retroviral vector.
Plasmids pLZR-b-ires-EGFP, pLZR-b-AR(LBD)-
ires-EGFP, pLZR-b-EGFP-AR(LBD) and pLZR-b-EGFP
were puriﬁed for transduction experiments with Qiagen
columns and further packaged in 293T cells as described
previously (12).
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NIH-3T3 and 293T cell lines were obtained from the
American Type Culture Collection (ATCC CRL-1658;
Manassas, VA). All cell lines were cultured in DMEM
(Life Technologies, Gaithersburg, MD) supplemented with
10% fetal bovine serum (Cultek, Madrid, Spain), 10 U/l peni-
cillin, 10 mg/ml streptomycin and 2 mM L-glutamine (Merck,
Darmstadt, Germany) (5% CO2,3 7  C).
Cell transfection
To obtain stable transformed cell lines of the recombination
psps-Luc construct and its control pLuc, plasmid DNA (20 mg)
was introduced in NIH-3T3 cells (2 · 10
6) by electroporation
at a concentration of 10
7 cells/ml in supplemented DMEM,
pulsed at 220 V, 950 mF (Gene Pulser; Bio-Rad, Hercules,
CA). Cells were replated and cultured (48 h), after which
selection antibiotics (200 mg/ml hygromycin B, 2 mg/ml pur-
omycin) were added to medium. Individual clones (sps-Luc),
obtained by limiting dilution, were collected and transduced
20–25 days after electroporation and selection.
Retroviral transduction
pLZR-b-ires-EGFP, pLZR-b-EGFP, pLZR-b-AR(LBD)-ires-
EGFP and pLZR-b-EGFP-AR(LBD) retroviral vectors were
packaged transiently in 293T as described previously (12).
Viral supernatants were titrated on NIH-3T3 cells on the
basis of EGFP ﬂuorescence and used to infect sps-Luc clones.
Transduction was performed using 1 ml of viral supernatant
(plus 8 mg/ml polybrene) added to the culture for 8 h, after
which medium was renewed. After 48 h, genomic DNA was
puriﬁed for PCR analysis using a miniprep puriﬁcation kit
(Qiagen)
Cell purification
Transduced EGFP-expressing cells were puriﬁed by cell sort-
ing. Cells were trypsin-treated, centrifuged, resuspended in
1 ml of phosphate-buffered saline (PBS) and FACS puriﬁed
using an EPICS Elite sorter (Coulter). Once isolated, each
EGFP
+ population was cultured without antibiotics, and 20–
25 days later genomic DNA was puriﬁed by PCR for recomb-
ination analysis.
Isolation and analysis of subclones
Subclones of one sps-Luc clone infected with the pLZR-b-
EGFP retroviral vector were obtained by limiting dilution,
replated and their recombination rates analyzed for 7 weeks
(samples were prepared after 5, 6 and 7 culture weeks). Cells
were washed, trypsinized and collected; genomic DNA was
puriﬁed as above and analyzed in PCR.
Androgen treatment
To determine the functionality of the inducible proteins,
mibolerone (DuPont, Boston, MA) dissolved in absolute
ethanol was added to the culture during exponential growth,
inaconcentration rangefrom10
 6to10
 8M.Controlcultures
received similar amounts of ethanol alone; ﬁnal ethanol con-
centrationsdid notexceed 0.01%(v/v).Luciferase assays were
performed 24, 48, 72 h or 6 days post-induction. For 6-day
inductions,culturemediumwithligandwasreplacedafter72h.
Analysis of recombination products
Transduced and non-transduced pools, isolated clones and
subclones were harvested from 6-well plates when they
reached conﬂuence. Genomic DNA was obtained by the
Easy-DNA method (Invitrogen) and 50 ng were used for
recombined substrate detection by PCR in a Perkin Elmer
thermocycler. We used the Expand Long Template PCR sys-
tem (Roche) as follows: 93 C for 2 min; 35 cycles of 94 C for
10 s; 49 C for 30 s; 68 C for 90 s and ﬁnal elongation at
68 C for 7 min. Primers for PCR detection were EF-1a-s
(50-GCACTTGA TGTAATTCTCC-30) and lucif-as (50-GT-
AAGTGATGTCCACCTCG-30). The PCR protocol was opti-
mized for ampliﬁcation not only of the recombined product
(0.6 kb band), but also of the non-recombined substrate (1.7 kb
band), which permitted us to measure the relative recombina-
tion rates between samples and to quantify the recombination
event.
Immunoblot
For immunoblot analysis, total proteins were extracted from
pLZRb-ires-EGFP, pLZRb-EGFP, pLZRb-AR(LBD)-ires-
EGFP and pLZRb-EGFP-AR(LBD)-transduced cells, sepa-
rated by SDS–PAGE and transferred to polyvinylidene
ﬂuoride membranes (Immunobilon-P, Millipore, Bedford,
MA) using a semidry blotting apparatus (Transblot-SD,
Bio-Rad). Antibodies used were anti-EGFP (mouse mAb
8362-1, 1:3000 dilution; Clontech, Palo Alto, CA), anti-b
recombinase [rabbit pAb, 1:500 (11)], anti-AR(LBD) (rabbit
pAb sc-815, 1:1000: Santa Cruz, Santa Cruz, CA), anti-tubulin
(mouse mAb T-9026, 1:500; Sigma, St Louis, MO) and anti-
histone H1 (mouse mAb sc-8030, 1:1000; Santa Cruz). After
immunobloting with secondary antibody, proteins were
visualized by chemiluminescent detection (ECL; Amersham
Pharmacia Biotech, Bucks., UK).
Confocal laser scanning
Transduced cells (103) were plated on a 35 mm glass coverslip
in 6-well plates and cultured for 24 h (when assaying inducible
recombination activity, ligand was added at this time). Cells
were ﬁxed (10 min) with 2% paraformaldehyde and 0.05%
Triton X-100 in PBS, and stained with rabbit anti-b recom-
binase [1:500 (11)] and anti-AR(LBD) (SC-815, 1:1000; Santa
Cruz Biotechnology). Secondary antibody was Cy3-labeled
goat anti-rabbit IgG (H+L) (111-166-008, 1:400; Amersham).
For Hoechst staining, cells were incubated with 0.8 mg/ml
Hoechst 33258 (Molecular Probes, Eugene, OR) for 5 min,
immediately after second antibody incubation. Cells were
mounted in Vectashield (Vector, Burlingame, CA) and
observed with a 63 · 1.4 oil-immersion lens. Images were
collected by confocal laser microscopy (Leica TCSNT),
noise-ﬁltered, corrected for background and processed using
Adobe Photoshop.
Luciferase assay
Infected cells were seeded into 6-well plates and harvested at
conﬂuence. Proteins were extracted and analyzed using the
Luciferase reporter assay (Promega) according to the manu-
facturer’s protocols. Cells were washed in 1· PBS and 250 ml
lysis reagent was added per well. Lysate was collected after
10 min and cleared by centrifugation (13000 r.p.m., 15 min).
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luminometer (Berthold Technologies, Vienna, Austria). Total
protein was quantiﬁed to normalize results. Data shown are
representative of at least three independent experiments.
RESULTS
C-terminal fusion proteins of b recombinase
maintain full activity
Two different vectors expressing b recombinase were con-
structed using pLZR (12) as retroviral backbone. One
expressed a direct fusion protein between the b recombinase
C-terminus andtheEGFPN-terminus;theotherisabicistronic
vector that expresses both proteins as individual ORFs
separated by the encephalomyocarditis virus RNA internal
ribosome entry site (IRES) (Figure 1A). These plasmids were
used to obtain high-titer supernatants by transient transfection
in 293T cells (see Materials and Methods). To verify the b
recombinase expression pattern using integrative retroviral
vectors context, we transduced NIH-3T3 cells with both vec-
tors. About 2–7 days later, proteins were extracted from
transduced cells and used to detect b recombinase and
EGFP by immunoblotting (Figure 1B). The autoradiograph
shows 23.4 and 27 kDa bands that correspond to b recombi-
nase and EGFP, respectively, with a 50 kDa band representing
the b-EGFP fusion protein.
Similar results were obtained when expression in trans-
duced cell was tested in immunoﬂuorescence with anti-b
recombinase antibody and EGFP autoﬂuorescence
(Figure 1C). Fluorescence microscopy of b-EGFP-expressing
cells showed exclusively nuclear localization of both
proteins, indicating that spontaneous subcellular localization
of b recombinase is not modiﬁed by fusion or the retroviral
dependent-context. A diffuse distribution pattern was detected
for EGFP in b-ires-EGFP cells, whereas b recombinase main-
tained its nuclear localization. These results concurred with
previous data for b-EGFP episomal expression plasmids (12),
demonstratingthe feasibility ofobtaining high,stable,uniform
b recombinase expression, as an independent or a fusion
protein in integrative retroviral vectors.
Experiments were developed to validate the potential of
these vectors in regulated expression systems. The psps-
Luc plasmid, in which gene expression is driven by the EF-
1a promoter, was developed as a recombination target
(Figure2A).Weinsertedapuromycinresistancegenebetween
two directed six sites; the luciferase gene was located down-
stream of the recombinant cassette, followed by a hygromycin
resistance gene. In this construct, luciferase expression is
impaired by the upstream puromycin stop codon; following
b recombinase expression, one six site and the entire puromy-
cin gene are deleted, including the stop codon; reporter gene
(luciferase) expression is thus allowed (Figure 2A). As a posi-
tive control, we used the same plasmid without the puromycin
gene or the six sites (pLuc).
NIH-3T3 cells were electroporated with these plasmids
(psps-Luc and pLuc) and hygromycin-resistant cells were
selected. The pool of resistant cells was transduced with
the b-ires-EGFP or b-EGFP retroviral vectors and luciferase
expression was measured after 48 h. We detected no luciferase
activity in the absence of b recombinase expression, but
luciferase expression levels were greatly increased in its
presence, alone or as a fusion protein (Figure 2B). Equivalent
recombination rates were obtained with both retroviral vec-
tors, indicating that the b-EGFP fusion protein retains most
of the catalytic activity shown by native b recombinase. This
result enables the design of novel b recombinase fusion pro-
teins using the C-terminus as the fusion point. All further
experiments were performed with the b-EGFP fusion protein.
b recombinase-mediated RAGE is
genomic context-dependent
To determine whether the genome integration sites of respon-
der plasmids inﬂuenced recombination effectiveness, we
obtained stable puromycin resistant psps-Luc-transfected
NIH-3T3 clones, each of which was transduced with the b-
EGFP retroviral vector; SSR was analyzed by PCR and
luciferase expression. Genomic DNA was isolated from
10 clones and ampliﬁed with speciﬁc primers of the EF-1a
promoter and the luciferase gene (Figure 2A), which allowed
us to estimate the relative recombination rates (Figure 3A,
upper panel). Ninety percent of clones showed substantial
recombination of the substrate structure; the recombination
level was also determined by quantiﬁcation of luciferase activ-
ity (Figure 3A, lower panel). To determine whether these
results were affected by differences in the percentage of
b-EGFP transduction, we puriﬁed the EGFP
+ population in
three clones (C7, C8 and C10) by cell sorting and analyzed
recombination by PCR (Figure 3B). This analysis showed an
improved net recombination in C7 and C8; C10 showed
roughly similar proportions for recombined and unrecombined
pools, indicating partial inhibition of b recombinase activity.
To analyze whether the results for C10 were due to chro-
matin inaccessibility, insufﬁcient recombinase expression, or
a reversible recombination process (absent in in vitro experi-
ments), we studied b-EGFP-transduced C10 subclones. Sev-
eralC10subclones wereobtainedbylimitingdilutionandtheir
recombination rates analyzed for 7 weeks (samples were pre-
pared after 5, 6 and 7 culture weeks). Some subclones showed
complete recombination from the start, whereas for others,
recombination rates improved with time (Figure 4A). These
differences appeared to be related to b recombinase levels, as
western blot analysis showed reduced expression in the less
efﬁcient clones (Figure 4B); b recombinase expression corre-
lated with molecular recombination rates as well as with rel-
ative luciferase activity (Figure 4C).
b recombinase-mediated RAGE regulation
using inducible systems
Theprevious resultshowedthatb-EGFPretainsfullenzymatic
activity; we thus used this strategy to test b recombinase
potential in an AR-based inducible system. We constructed
two retroviral vectors containing b recombinase and the AR-
LBD asfusion proteins(Figure 5A).In theﬁrst,we generateda
bicistronic vector that fused b recombinase to the LBD (b-
AR), permitting independent IRES-driven EGFP expression;
in the second, we fused b recombinase to EGFP and LBD in a
triple fusion protein (b-EGFP-AR). As recombination sub-
strate, we used the previously tested clones (C7, C8 and C10).
Based on previous results using the androgen receptor
LBD (AR-LBD) to control FLP and Cre recombinase enzyme
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nase fusion proteins in cytoplasm, impeding access to their
genomic target recombination sequences. Following ligand
administration (mibolerone), AR-LBD would prevent further
cytoplasmic interactions; b-AR and b-EGFP-AR would
subsequently be able to translocate to the nucleus via the b
recombinase nuclear localization signal. Once in the nucleus,
the b recombinase domain would gain access to its targets.
C7, C8 and C10 cells were transduced with both retroviral
vectors and selected by cell sorting. Luciferase activity was
Figure 1. b Recombinase expression using retroviral vectors. (A) Scheme of LZR-b-EGFP and LZR-b-ires-EGFP retroviral vectors used. Expression of a direct
fusionproteinbetweenbrecombinaseandEGFP(upper);independentexpressionofbothproteinsusinganIRES(lower).Arrowsindicatethetranscribedsequence.
(B) NIH-3T3 cells were transduced with both vectors; after 48 h, total proteins were extracted. Western blot autoradiograph shows expression of the fusion protein
(b-EGFP,50kDa,leftlane),individualproteins(b,23.4kDa;EGFP,27kDa,right)and5ngofpurifiedbrecombinase(center).Non-specificbandsaremarkedwith
an asterisk on the membranes. (C) Immunofluorescence of NIH-3T3 cells transduced with LZR-b-EGFP (upper) and LZR-b-ires-EGFP (lower), showing
nuclear localization of b recombinase, fused or alone. EGFP is detected in the same nuclear dots when LZR-b-EGFP is used, but not when b recombinase
and EGFP are expressed independently (LZR-b-ires-EGFP). TOPRO stains nuclei.
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+ fraction, for different
mibolerone concentrations and induction times.
To quantify induced and uninduced fusion protein levels,
we developed a western blot using antibodies to b recombi-
nase, EGFP and AR-LBD. The bands for mibolerone-treated
cells showed a lesser intensity than those of controls. EGFP
levels were similar in cells transduced with bicistronic vectors,
in which EGFP is expressed independently (Figure 5B). To
conﬁrm this effect and protein loading equivalence, blots were
stained with anti-histone1 and anti-tubulin control antibodies;
intensity of all samples was measured and normalized with
controls. We calculated a 30 and 50% decrease in fusion
protein expression in mibolerone-treated cells for double-
and triple-fusion proteins, respectively.
In addition, we studied fusion protein subcellular localiza-
tion by immunocytochemistry, before and after mibolerone
treatment. Transduced cells were ﬁxed and stained with
anti-b recombinase or anti-LBD antibody; EGFP was visual-
ized directly in a ﬂuorescence microscope. As predicted, the
EGFP signal was throughout-diffused in cells transduced with
the bicistronic vector; the fusion protein localized to cyto-
plasm before and primarily to the nucleus after mibolerone
treatment (Figure 5C). Following mibolerone treatment, the
triple fusion protein localized exclusively in the nucleus; in
untreated cells, this protein was found in the cytoplasm as well
as in nuclear aggregates (Figure 5D).
In both groups of cells, mibolerone treatment upregulated
luciferase expression; the treated triple fusion protein cells had
the highest luciferase levels, but also their untreated control
cells showed more background values than untreated double
fusion protein cells (data not shown). In this regard, normal-
ized luciferase activity in mibolerone-treated cells was higher
in cells transduced with the double fusion protein than with the
triple fusion protein, indicating better regulation of the b
recombinase-dependent RAGE system (Figure 6).
DISCUSSION
Site-speciﬁc recombinases have been established as powerful
tools for gene manipulation and the generation of genetically
modiﬁed living organisms (3). Two classes of these enzymes
have been studied in detail, both of which store the energy of
a broken DNA phosphodiester bond in covalent protein–DNA
intermediates; depending on the choice of nucleophile, they
are referred to as serine or tyrosine recombinases [reviewed
in (25)].
The most widely used SSR models are the Cre-loxP system
derived from bacteriophage P1, and Flp-FRT from the yeast
Saccharomyces cerevisae. Both have demonstrated versatility
for strict spatio-temporal control of the genomic modiﬁcation
induced, eliminating the consequences of undesired effects
due to systemic lack of an essential gene (26,27) or bypass
effects due to unforeseeable redundancy that produces no
detectable phenotypic changes (28,29).
Cre and Flp belong to one of the major families of site-
speciﬁc recombinases, the tyrosine recombinases. These
enzymes cleave, exchange and rejoin one pair of DNA strands,
generating a Holliday junction as a recombination intermedi-
ate before initiating these reactions on the other pair of DNA
strands.Thereactionoutput(integration,deletion orinversion)
depends on the existence of recombination sites in the same or
in distinct molecules and their relative orientation [reviewedin
(25,30)].
The other major SSR family is that of the serine
recombinases, which comprises two subfamilies; the small
recombinases (<250 amino acids), which catalyze mainly
intramolecular recombinations, and the large recombinases
(>450 amino acids), which catalyze both inter- and intra-
molecular reactions [reviewed in (30)]. The small recombi-
nases can again be subdivided into three groups, which
catalyze resolution (resolvases such as gd and Tn3), inversion
(invertases such as Hin and Gin) or both (resolvase-invertases
Figure 2. Retroviral vector potential in regulated expression systems.
(A) Scheme for target plasmids used. psps-Luc plasmid, in which a puro-
mycin gene is located between two directed six sites under the control of an
EF-1a promoter (upper). A luciferase gene is inserted downstream, followed
by a hygromycin resistance gene. b Recombinase expression causes deletion
of the puromycin gene including its stop codon and one six site, allowing
luciferase reporter gene expression. Positive control plasmid (pLuc) with
direct luciferase expression, under the same promoter (lower). Arrows indi-
cate transcription units and arrowheads indicate specific primers used to
detect recombination. (B) NIH-3T3 cells were electroporated with psps-Luc
and pLuc, and hygromycin-resistant cells were selected. psps-Luc NIH-
3T3-resistant cells were transduced with b-EGFP or b-ires-EGFP retroviral
vectors; luciferase expression was measured after 48 h. The negative sample
(neg) involves transduction of psps-Luc NIH-3T3-resistant cells with a control
vector.
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four-strand cleavage and rejoining mechanism [reviewed in
(30)], best explained by a recombinase subunit rotation model
during DNA synapsis [reviewed in (25)]. Resolvase-invertases
are peculiar, as they do not have the same high selectivity as
resolvases and invertases for resolution or inversion [reviewed
in (30)]; for example, b recombinase can catalyze resolution
between two directly oriented recombination sites, and both
resolution and inversion between two inversely oriented sites
(31).Itwasproposedthatthedistinctive propertiesofbrecom-
binase are more likely due to a degree of ﬂexibility in the
structure and assembly of the synaptic complex, than to any
difference in the strand exchange mechanism (30).
We recently described the potential application of a new
SSR system based on b recombinase for manipulation of the
mammalian genome (11,12). In contrast to Cre-loxP and Flp-
FRT systems, the in vitro requirements of the b-six model
include a host protein factor and a supercoiled substrate to
catalyze resolution reactions (32); those requirements seem to
beprovidedbythemammalianchromatinenvironment(11,12).
The versatility of SSR systems is based on their potential to
be controlled in an inducible manner, which was shown to be
feasible and efﬁcient for the Cre-loxP and Flp-FRT systems
(33–35) using fusions of recombinase activity to receptor LBD
in several hormone systems. Studies also indicated that EGFP
fusion to the b recombinase C-terminus does not abolish its
recombinogeniccapacity,openingthewayforevaluationofan
inducible b-six model (12).
Using improved retroviral expression vectors, we show here
that the speciﬁc catalytic activity of the b-EGFP protein is
Figure 3. Analysisofrecombinationinpsps-Luc-transducedNIH-3T3clones.Tenclones(1–10)wereisolatedandSSRanalyzedbyPCRandluciferaseexpression.
(A) Genomic DNA of each clone ( , untransduced cells; +, transduced cells) was amplified using specific primers of the EF-1a promoter and luciferase gene
(seeFigure2A).Non-recombinedDNA(NR;1.5kbband),recombinedDNA(R;0.4kbband)(upperpanel).Therecombinationlevelwasdeterminedbyluciferase
activity quantification(lower panel). (B) EGFP-positive subpopulations were purified by cell sorting of three different clones (7, 8 and 10). Recombination level in
untransduced ( ) and transduced (pre-sorting and post-sorting) cells was analyzed by PCR.
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eukaryotic environments. We thus used this fusion scheme to
evaluate a potential b-six-dependent inducible recombination
system (b-SSR). To test the inﬂuence of the chromosomal
integration environment on the effectiveness of the b-SSR
system, we analyzed several parameters and characterized
the responder clones (NIH-3T3-sps-Luc). We found that
90% of the integration sites are accessible to the b recombi-
nase activity, although there were notable differences in efﬁ-
ciency. We obtained several subclones of a selected cloned
cell line, which harbored the same recombination substrate but
different b recombinase expression levels due to random retro-
viral expression vector integration. This allowed us to analyze
the inﬂuence of b recombinase expression levels on the
recombination rate, independently of substrate positional con-
straints. We found strong correlation between recombination
effectiveness and b recombinase expression, suggesting that
an undetermined minimal amount of b recombinase is neces-
sary forSSR,probablyinagenomicintegrationsite-dependent
manner.
The b-SSR was obtained by replacing the EGFP module of
b-EGFPproteinwiththehumanAR-LBD (b-AR)orbyadding
AR-LBD to the b-EGFP protein (b-EGFP-AR). Based on
earlier models (36,37), these two fusion proteins would remain
inactive in cytoplasm until stimulated by a receptor agonist
(mibolerone) that promotes nuclear translocation and recomb-
ination of the responder substrate.
In the b-AR-expressing cells, b-AR accumulated in cyto-
plasm, with partial translocation to the nucleus only after
mibolerone treatment. Mibolerone treatment of b-EGFP-
AR-expressing cells promoted complete translocation to the
nucleus. When these cells were not treated, however, the
b-EGFP-AR fusion protein was distributed throughout
the cell, with nuclear foci, anticipating a probable higher
basal background. We conﬁrmed the expression levels of
both fusion proteins in untreated and mibolerone-treated
cells in western blot, using anti-b recombinase, anti-EGFP
and anti-LBD antibodies. Total fusion protein decreased
after mibolerone administration (30 and 50% decrease in
b-AR and b-EGFP-AR expression, respectively); control
anti-EGFP antibody in b-AR-expressing cells showed no sig-
niﬁcant decrease. The data thus strongly suggest that the
presence of the AR-LBD appears to decrease fusion protein
half-life after mibolerone treatment. Previous studies indi-
cated that the AR N-terminal region is necessary for receptor
stabilization (38). Stabilization is agonist-induced and pre-
vents ubiquitin-mediated degradation by the proteosome.
Deletion or mutation of this region accelerates normal
degradation when the AR is bound to the agonist (39). Our
data using an N-terminal-deﬁcient AR-LBD concur with these
results.
Evaluation of the inducible luciferase reporter levels cor-
roborated that it increased after mibolerone treatment of trans-
duced cells expressing both fusions. Following induction,
absolute luciferase levels were higher for cells expressing
b-EGFP-AR protein than b-AR, although untreated b-
EGFP-AR control cells also showed a higher luciferase back-
ground. The diminished protein amount in treated triple fusion
protein cells, in addition to its higher background in control
cells, could explain the lower up-regulation shown for this
fusion in data from Figure 6.
These functional results concur with the subcellular local-
ization described for these fusion proteins. The literature
shows contradictory ﬁndings on basal AR localization,
depending on the cell line and immunocytochemical proce-
dure used, expression level and the fusion partner (40–42);
probably the same undeﬁned factors could be affecting our
experimental design explaining, at least in part, the higher
luciferase background founded in untreated cells.
These results demonstrate the feasibility of combining
the requirements for an accurate inducible system with the
SSR mediated by this b recombinase. Further work would
provide a well-regulated system for controlled deletion of
selected target sequences, which could be used in combination
with Cre-loxP and Flp/FRT, the systems of choice for condi-
tional targeting.
Figure 4. Analysis of recombination time-course. Several C10 subclones were obtained and their recombination rates analyzed over a 7-week period. The
recombination rate obtained for five of them (10.2, 10.3, 10.5, 10.6 and 10.7) was analyzed by several techniques. (A) Non-recombined (NR) and recombined
(R)DNAfragmentsamplifiedbyPCR.(B) Detectionofbrecombinase expressionandhistoneH1,ascontrol,bywesternblot.(C)Luciferaseactivity.Westernblot
and luciferase activity were measured in the fifth week.
e1 Nucleic Acids Research, 2006, Vol. 34, No. 1 PAGE 8 OF 11Figure 5. SSR using an inducible system based on fusion of b recombinase and the androgen receptor. (A) Scheme showing the retroviral vectors used in the
inducible system. LZR-b-EGFP-(AR)LBD vector expresses the triple fusion protein (b-EGFP-LBD) of b recombinase, EGFP and the androgen receptor LBD
(upper); the lower panel shows LZR-b-(AR)LBD-ires-EGFP vector which allows independent expression of the b-LBD fusion protein and EGFP by an IRES.
Arrows indicate transcription units. (B) C7, C8 and C10 clones were transduced with the retroviral vectors and the EGFP-positive subpopulation selected by cell
sorting.Westernblotshowsexpressionofb-EGFP-LBD(80kDa),b-LBD(54kDa),EGFP(27kDa),andtubulin(control,55kDa)intransducedcells,untreated( )
or treated with (+) mibolerone (Mib; 10
 8 M, 48 h). Non-specific bands are marked with an asterisk on the membranes. (C) Immunocytochemistry of b-LBD-
ires-EGFP-expressing cells, alone or mibolerone-treated. (D) Immunocytochemistry of b-EGFP-LBD-transduced cells, alone or with mibolerone. Only data
obtained in clone C8 have been included in (B–D). Clones C7 and C10 rendered quite similar results.
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